Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target

Ghassan M. Saed, Nicole M. Fletcher, Michael Peter Diamond, Robert T. Morris, Nardhy Gomez-Lopez, Ira Memaj

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The objective of this study was to determine the expression, and effect of targeting CD11b with a monoclonal antibody in ovarian cancer cells. Methods: CD11b expression was determined in epithelial ovarian cancer (EOC) cell lines and tissues by immunofluorescence and flow cytometry. Cytotoxicity of the CD11b antibody and synergism with chemothearapeutic drugs were determined by the MTT Cell Proliferation Assay in human macrophages, normal ovarian epithelial cells, and in both sensitive and chemoresistant EOC cell lines. Cell migration was assessed with a scratch assay and in vivo effects of the CD11b antibody was assessed with a nude mouse ovarian cancer xenograft model. Data was analyzed with either t-tests or one-way ANOVA. Results: CD11b was unexpectedly expressed in several EOC lines and tissues, but not normal tissues. Targeting CD11b with its monoclonal antibody resulted in intriguing cytotoxic effects in sensitive and chemoresistant EOC lines, while surprisingly not affecting normal cells. More importantly, the cytotoxicity of the CD11b antibody when combined with chemotherapeutic drugs (cisplatin or docetaxel) was significantly synergistic, in both sensitive and chemoresistant EOC cells. The anti-tumorigenic effect of the CD11b antibody was confirmed in an ovarian cancer nude mouse xenograft model. Conclusion: Here we identify CD11b as a novel target, which selectively induces cytotoxicity in ovarian cancer cells.

Original languageEnglish (US)
Pages (from-to)567-575
Number of pages9
JournalGynecologic Oncology
Volume148
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Ovarian Neoplasms
Antibodies
docetaxel
Heterografts
Nude Mice
Monoclonal Antibodies
Therapeutics
Cell Line
Pharmaceutical Preparations
Cisplatin
Cell Movement
Fluorescent Antibody Technique
Analysis of Variance
Flow Cytometry
Epithelial Cells
Macrophages
Cell Proliferation
Ovarian epithelial cancer

Keywords

  • Apoptosis
  • CD11b
  • CD11b antibody
  • Cytotoxicity
  • Myeloperoxidase
  • Survival mechanism

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Novel expression of CD11b in epithelial ovarian cancer : Potential therapeutic target. / Saed, Ghassan M.; Fletcher, Nicole M.; Diamond, Michael Peter; Morris, Robert T.; Gomez-Lopez, Nardhy; Memaj, Ira.

In: Gynecologic Oncology, Vol. 148, No. 3, 01.03.2018, p. 567-575.

Research output: Contribution to journalArticle

Saed, Ghassan M. ; Fletcher, Nicole M. ; Diamond, Michael Peter ; Morris, Robert T. ; Gomez-Lopez, Nardhy ; Memaj, Ira. / Novel expression of CD11b in epithelial ovarian cancer : Potential therapeutic target. In: Gynecologic Oncology. 2018 ; Vol. 148, No. 3. pp. 567-575.
@article{f32dcad1171b4b9c95b6b1f09068cf30,
title = "Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target",
abstract = "Objective: The objective of this study was to determine the expression, and effect of targeting CD11b with a monoclonal antibody in ovarian cancer cells. Methods: CD11b expression was determined in epithelial ovarian cancer (EOC) cell lines and tissues by immunofluorescence and flow cytometry. Cytotoxicity of the CD11b antibody and synergism with chemothearapeutic drugs were determined by the MTT Cell Proliferation Assay in human macrophages, normal ovarian epithelial cells, and in both sensitive and chemoresistant EOC cell lines. Cell migration was assessed with a scratch assay and in vivo effects of the CD11b antibody was assessed with a nude mouse ovarian cancer xenograft model. Data was analyzed with either t-tests or one-way ANOVA. Results: CD11b was unexpectedly expressed in several EOC lines and tissues, but not normal tissues. Targeting CD11b with its monoclonal antibody resulted in intriguing cytotoxic effects in sensitive and chemoresistant EOC lines, while surprisingly not affecting normal cells. More importantly, the cytotoxicity of the CD11b antibody when combined with chemotherapeutic drugs (cisplatin or docetaxel) was significantly synergistic, in both sensitive and chemoresistant EOC cells. The anti-tumorigenic effect of the CD11b antibody was confirmed in an ovarian cancer nude mouse xenograft model. Conclusion: Here we identify CD11b as a novel target, which selectively induces cytotoxicity in ovarian cancer cells.",
keywords = "Apoptosis, CD11b, CD11b antibody, Cytotoxicity, Myeloperoxidase, Survival mechanism",
author = "Saed, {Ghassan M.} and Fletcher, {Nicole M.} and Diamond, {Michael Peter} and Morris, {Robert T.} and Nardhy Gomez-Lopez and Ira Memaj",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2017.12.018",
language = "English (US)",
volume = "148",
pages = "567--575",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Novel expression of CD11b in epithelial ovarian cancer

T2 - Potential therapeutic target

AU - Saed, Ghassan M.

AU - Fletcher, Nicole M.

AU - Diamond, Michael Peter

AU - Morris, Robert T.

AU - Gomez-Lopez, Nardhy

AU - Memaj, Ira

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: The objective of this study was to determine the expression, and effect of targeting CD11b with a monoclonal antibody in ovarian cancer cells. Methods: CD11b expression was determined in epithelial ovarian cancer (EOC) cell lines and tissues by immunofluorescence and flow cytometry. Cytotoxicity of the CD11b antibody and synergism with chemothearapeutic drugs were determined by the MTT Cell Proliferation Assay in human macrophages, normal ovarian epithelial cells, and in both sensitive and chemoresistant EOC cell lines. Cell migration was assessed with a scratch assay and in vivo effects of the CD11b antibody was assessed with a nude mouse ovarian cancer xenograft model. Data was analyzed with either t-tests or one-way ANOVA. Results: CD11b was unexpectedly expressed in several EOC lines and tissues, but not normal tissues. Targeting CD11b with its monoclonal antibody resulted in intriguing cytotoxic effects in sensitive and chemoresistant EOC lines, while surprisingly not affecting normal cells. More importantly, the cytotoxicity of the CD11b antibody when combined with chemotherapeutic drugs (cisplatin or docetaxel) was significantly synergistic, in both sensitive and chemoresistant EOC cells. The anti-tumorigenic effect of the CD11b antibody was confirmed in an ovarian cancer nude mouse xenograft model. Conclusion: Here we identify CD11b as a novel target, which selectively induces cytotoxicity in ovarian cancer cells.

AB - Objective: The objective of this study was to determine the expression, and effect of targeting CD11b with a monoclonal antibody in ovarian cancer cells. Methods: CD11b expression was determined in epithelial ovarian cancer (EOC) cell lines and tissues by immunofluorescence and flow cytometry. Cytotoxicity of the CD11b antibody and synergism with chemothearapeutic drugs were determined by the MTT Cell Proliferation Assay in human macrophages, normal ovarian epithelial cells, and in both sensitive and chemoresistant EOC cell lines. Cell migration was assessed with a scratch assay and in vivo effects of the CD11b antibody was assessed with a nude mouse ovarian cancer xenograft model. Data was analyzed with either t-tests or one-way ANOVA. Results: CD11b was unexpectedly expressed in several EOC lines and tissues, but not normal tissues. Targeting CD11b with its monoclonal antibody resulted in intriguing cytotoxic effects in sensitive and chemoresistant EOC lines, while surprisingly not affecting normal cells. More importantly, the cytotoxicity of the CD11b antibody when combined with chemotherapeutic drugs (cisplatin or docetaxel) was significantly synergistic, in both sensitive and chemoresistant EOC cells. The anti-tumorigenic effect of the CD11b antibody was confirmed in an ovarian cancer nude mouse xenograft model. Conclusion: Here we identify CD11b as a novel target, which selectively induces cytotoxicity in ovarian cancer cells.

KW - Apoptosis

KW - CD11b

KW - CD11b antibody

KW - Cytotoxicity

KW - Myeloperoxidase

KW - Survival mechanism

UR - http://www.scopus.com/inward/record.url?scp=85040217791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040217791&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.12.018

DO - 10.1016/j.ygyno.2017.12.018

M3 - Article

C2 - 29329880

AN - SCOPUS:85040217791

VL - 148

SP - 567

EP - 575

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -